Targeting the MCT1 dependent lactate transport could be therefore a novel option in PDAC therapy, particularly by eliminating cancer stem cell-like cells deriving from metabolic restraints in the tumor and giving rise to recurrence upon conventional cancer therapy. This evidence concerns the gene SLC16A1 and cancer.